Caelus Health
Specializing in microbiota-based products, Caelus Health targets cardiometabolic diseases. Their research focuses on beneficial bacterial strains that improve insulin sensitivity and metabolic health. Their first product is a precision probiotic supplement for prediabetes and type 2 diabetes.
AMI Pharma
AMI Pharma develops therapeutics compounds for Type 1 Diabetes and autoimmune diseases. Their research, based on IP from Amsterdam UMC and Wageningen University & Research, aims to bring new treatments to the clinical trials. AMI Pharma leverages extensive pre-clinical and clinical data to advance their therapeutic pipeline.
